Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial

Next Previous
Trial Profile

Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCT 100 (Primary) ; Cytarabine (Primary) ; Ganetespib (Primary) ; Lenalidomide (Primary) ; Quizartinib (Primary) ; Sapacitabine (Primary) ; Selinexor (Primary) ; Tosedostat (Primary) ; Vosaroxin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AML-LI-1; AML-LI1; AMLM20; LI-1

    • Most Recent Events

    • 01 Mar 2024 Results assessing efficacy of lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone published in the British Journal of Haematology
    • 01 Mar 2023 Results (n=83) published in the British Journal of Haematology
    • 14 Dec 2021 Results assessing the efficacy of LDAC+BCT100 versus LDAC alone in patients aged 60+ unsuitable for intensive therapy presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top